Literature DB >> 9726590

Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease.

J Seissler1, J J de Sonnaville, N G Morgenthaler, H Steinbrenner, D Glawe, U Y Khoo-Morgenthaler, M S Lan, A L Notkins, R J Heine, W A Scherbaum.   

Abstract

Type I diabetes mellitus may represent a heterogeneous disorder with a distinct pathogenesis in patients with young and adult onset of the disease. To investigate whether serological markers directed to different autoantigens have the potential to distinguish acute onset from slowly progressive Type I diabetes we analysed antibodies to tyrosine phosphatases IA-2/ICA512 (IA-2A) and IA-2beta/phogrin (IA2betaA), antibodies to GAD65 (GADA) and cytoplasmic islet cell antibodies (ICA) in a non-selected group of diabetic patients clinically classified as having Type I or Type II diabetes at diagnosis. Both IA-2A and IA-2betaBA were found to be positively associated with onset before the age of 20 years and the presentation of classical features of Type I diabetes. In Type I diabetes 56 % (112/200) of patients were positive for IA-2A and 38 % (76/200) for IA-2betaA. In contrast, only 1 of 785 (0.1 %) patients with Type II diabetes had IA-2A and all of them were negative for IA-2betaA (p < 0.001). Among the patients with Type II diabetes 7.6% (n = 60) were ICA positive and 2.8% (n = 22) had GADA suggesting the presence of slowly progressive Type I diabetes. GADA were found in 8 of 60 (13.3 %) ICA positive subjects which was lower than the percentage detected in patients with acute onset of diabetes (115/157 73.2%) (p < 0.001). Blocking of double antibody positive sera showed that only 3 of 8 (37.5 %) patients with slowly progressive diabetes had ICA restricted to GAD or IA-2 whereas ICA were completely inhibited in 12 of 20 (60.0 %) patients with Type I diabetes. Among 193 patients with Type II diabetes available for follow-up, 35 % of ICA positives, 58 % of GADA positives and 60 % of those positive for both markers required insulin by 3 years. However, using strict criteria for the switch to insulin treatment the corresponding sensitivity of each marker was only low (9%, 10% and 5%). We show that clinical subtypes of Type I diabetes are associated with distinct humoral autoimmunity. IA-2A and GADA were associated with classical features of Type I diabetes whereas GADA and an uncharacterized ICA subspecificity indicate slowly progressive disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726590     DOI: 10.1007/s001250051004

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

1.  Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2.

Authors:  J Seissler; M Schott; N G Morgenthaler; W A Scherbaum
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Latent autoimmune diabetes in adults (LADA).

Authors:  Ramachandra G Naik; Jerry P Palmer
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 3.  Autoimmune diabetes: more than just one flavor?

Authors:  H K Chiu; J P Palmer
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

Review 4.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

5.  Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adult people (15-34 yrs) in the Diabetes Incidence Study in Sweden (DISS).

Authors:  H Borg; H J Arnqvist; E Björk; J Bolinder; J W Eriksson; L Nyström; J-O Jeppsson; G Sundkvist
Journal:  Diabetologia       Date:  2003-02-08       Impact factor: 10.122

6.  Exposure Cessation During Adulthood Did Not Prevent Immunotoxicity Caused by Developmental Exposure to Low-Level Trichloroethylene in Drinking Water.

Authors:  Kathleen M Gilbert; Shasha Bai; Dustyn Barnette; Sarah J Blossom
Journal:  Toxicol Sci       Date:  2017-06-01       Impact factor: 4.849

Review 7.  Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation.

Authors:  B Brooks-Worrell; J P Palmer
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

8.  Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway.

Authors:  E P Sørgjerd; F Skorpen; K Kvaløy; K Midthjell; V Grill
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

9.  The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset.

Authors:  M Hillman; C Törn; M Landin-Olsson
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

10.  The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments.

Authors:  Chun Shi Jia; Jiang Ning Liu; Wan Bo Li; Chun Mei Ma; Shu Zhu Lin; Yi Hao; Xue Zhong Gao; Xiao Lin Liu; Yan Feng Xu; Lian Feng Zhang; Chuan Qin
Journal:  Virol J       Date:  2010-02-22       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.